A companhia opera no Brasil pelas empresas Panpharma, que detém 15 por cento de participação do mercado de distribuição nacional de medicamentos, e a Oncoprod, voltada a medicamentos de alta complexidade.
A Celesio havia incluído a Panpharma em seu grupo em 2012 e completado a aquisição de 40 por cento da Oncoprod que ainda não possuía em agosto do ano passado.
"Esta decisão está alinhada à estratégia da Celesio de fortalecer sua posição de mercado na Europa", afirmou Marc Owen, presidente do Conselho de Administração da Celesio, em breve comunicado ao mercado.
Com a decisão, o presidente-executivo da Celesio no Brasil, Alexander Triebnigg, decidiu deixar a companhia. As operações brasileiras serão dirigidas interinamente por Gustavo Kotscho, Hanns Martin Lipp e Herminio Tavares.
Em 2014, a receita da divisão de soluções para farmácias da Celesio no Brasil caiu 4 por cento, a 1,68 bilhão de euros, segundo resultado anual da companhia alemã, que cita depreciação do real, impactos contábeis, lentidão no ritmo de reestruturação de negócios no país e consolidação de redes de farmácias como elemento de pressão sobre margens de lucro. (Por Alberto Alerigi Jr., edição de Luciana Bruno) Reuters leia mais em Yahoo 27/04/2015
============
Celesio announces intention to sell its Brazilian operations
Supports Celesio’s business focus on European markets
Stuttgart, 27 April 2015
Celesio AG, a leading international wholesale and retail company and provider of logistics and services to the pharmaceutical and healthcare sectors, today announced its intention to sell its Brazilian subsidiaries following a business review of its operations within the country. Celesio’s Brazilian operations include Panpharma and Oncoprod, both of which are 100% owned by Celesio.
Press release (PDF, 160 KB)
Celesio has a strong footprint in Europe. In selling its Brazilian operations, Celesio will increase its focus on European markets and customers.
Commenting on the intention to sell, Marc Owen, Chairman of the Management Board at Celesio, said: “This business decision aligns with Celesio’s strategy to strengthen our market position in Europe.”
In conjunction, Dr Alexander Triebnigg, Managing Director of Celesio’s Brazilian operations, informed the company that he has decided to leave the business.
Dr Andreas Windischbauer, Managing Director Austria and responsible for Brazil, said of Dr Alexander Triebnigg’s decision to leave Panpharma and Oncoprod: “I would like to take this opportunity to thank Dr Alexander Triebnigg for his hard work and commitment and we wish him the best with his future endeavours.”
In the interim the business will be managed jointly by Gustavo Kotscho, Martin Lipp and Herminio Tavares. Gustavo Kotscho joined Celesio in 2011. Martin Lipp has been with Celesio since September, 2014. Herminio Tavares recently re-joined Panpharma and Oncoprod after previously spending 19 years with Celesio.
Dr Andreas Windischbauer added: “In Gustavo Kotscho, Martin Lipp and Herminio Tavares we have a strong and experienced management team in place, who are well positioned to lead the business in a manner that will benefit all parties and stakeholders.”
About the Celesio Group
Celesio is a leading international wholesale and retail company and provider of logistics and services to the pharmaceutical and healthcare sectors. The proactive and preventive approach ensures that patients receive the products and support that they require for optimum care. With some 39,000 employees, Celesio operates in 14 countries around the world. Every day, the group serves over 2 million customers – at about 2,200 pharmacies of its own and over 4,300 participants in brand partnership schemes. With 133 wholesale branches, Celesio supplies 65,000 pharmacies and hospitals every day with up to 130,000 pharmaceutical products. The services benefit a patient pool of about 15 million per day.
McKesson Corporation, San Francisco, USA, is the majority shareholder in Celesio AG. The company acquired more than 75 percent of Celesio AG shares in February 2014. McKesson provides solutions that include pharmaceutical and medical-surgical supply management, healthcare information technology, and business and clinical services.
About Panpharma and Oncoprod
Panpharma is a Brazilian pharmaceutical wholesaler and operates from 14 distribution centres, moving around 1 million pharmaceutical units each day. The Goiania based company has more than 3,600 employees.
Oncoprod, located in Sao Paulo, is the only distributor in Brazil to focus solely on specialty pharmaceuticals, operating with seven branches throughout the country and has more than 300 employees. Leia mais em Celesio 27/04/2015
Nenhum comentário:
Postar um comentário